These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12783202)

  • 1. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
    Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
    D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
    Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
    Takahashi N; Li W; Banerjee D; Guan Y; Wada-Takahashi Y; Brennan MF; Chou TC; Scotto KW; Bertino JR
    Cancer Res; 2002 Dec; 62(23):6909-15. PubMed ID: 12460906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
    Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
    Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
    Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
    Takahashi N; Li WW; Banerjee D; Scotto KW; Bertino JR
    Clin Cancer Res; 2001 Oct; 7(10):3251-7. PubMed ID: 11595721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
    Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
    Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
    Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
    Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
    Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
    Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.